Literature DB >> 29336855

Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018.

Steven Fishbane1, Bruce Spinowitz2.   

Abstract

Anemia is a frequent complication during the later stages of chronic kidney disease. When present, it may cause symptoms such as fatigue and shortness of breath. The pathogenesis of anemia in chronic kidney disease is complex, but a central feature is a relative deficit of erythropoietin. New information has elucidated the critical role of the hypoxia-sensing system in mediating erythropoietin synthesis and release. Iron deficiency is a second important factor in the anemia of chronic kidney disease. New insights into the dynamics of iron metabolism have clarified the role of chronic inflammation and hepcidin as key mediators of impaired iron utilization. In this article, we review the epidemiology, pathobiology, clinical evaluation, and treatment of anemia in chronic kidney disease.
Copyright © 2017 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  anemia; cardiovascular disease; chronic kidney disease (CKD); darbepoeitin alfa; epoetin alfa; erythropoiesis; erythropoiesis-stimulating agent (ESA); erythropoietin deficiency; fatigue; hemoglobin; iron; quality of life; review

Mesh:

Substances:

Year:  2018        PMID: 29336855     DOI: 10.1053/j.ajkd.2017.09.026

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  53 in total

Review 1.  Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease.

Authors:  Jodie L Babitt; Despina Sitara
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

Review 2.  Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach.

Authors:  Zahra Moradi; Amirhosein Maali; Javad Sadeghi Shad; Alireza Farasat; Reza Kouchaki; Mona Moghadami; Mohamad Hosein Ahmadi; Mehdi Azad
Journal:  Indian J Hematol Blood Transfus       Date:  2019-09-16       Impact factor: 0.900

Review 3.  The role of iron repletion in adult iron deficiency anemia and other diseases.

Authors:  Benjamin Elstrott; Lubna Khan; Sven Olson; Vikram Raghunathan; Thomas DeLoughery; Joseph J Shatzel
Journal:  Eur J Haematol       Date:  2019-12-26       Impact factor: 2.997

Review 4.  Trajectories of kidney function in diabetes: a clinicopathological update.

Authors:  Megumi Oshima; Miho Shimizu; Masayuki Yamanouchi; Tadashi Toyama; Akinori Hara; Kengo Furuichi; Takashi Wada
Journal:  Nat Rev Nephrol       Date:  2021-08-06       Impact factor: 28.314

Review 5.  Treatment of Renal Anemia with Roxadustat: Advantages and Achievement.

Authors:  Zuo-Lin Li; Yan Tu; Bi-Cheng Liu
Journal:  Kidney Dis (Basel)       Date:  2020-01-10

6.  A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.

Authors:  Tadao Akizawa; Yusuke Yamaguchi; Tetsuro Otsuka; Michael Reusch
Journal:  Nephron       Date:  2020-06-24       Impact factor: 2.847

7.  The Optimal Haemoglobin Target in Dialysis Patients May Be Determined by Its Contrasting Effects on Arterial Stiffness and Pressure Pulsatility.

Authors:  Hon-Chun Hsu; Chanel Robinson; Gavin R Norton; Angela J Woodiwiss; Patrick H Dessein
Journal:  Int J Nephrol Renovasc Dis       Date:  2020-12-30

8.  Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.

Authors:  Tadao Akizawa; Masaomi Nangaku; Taeko Yonekawa; Nobuhiko Okuda; Shinya Kawamatsu; Tomohiro Onoue; Yukihiro Endo; Katsutoshi Hara; Alexander R Cobitz
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-28       Impact factor: 8.237

Review 9.  Roxadustat: First Global Approval.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

10.  Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.

Authors:  Steven Fishbane; Mohamed A El-Shahawy; Roberto Pecoits-Filho; Bui Pham Van; Mark T Houser; Lars Frison; Dustin J Little; Nicolas J Guzman; Pablo E Pergola
Journal:  J Am Soc Nephrol       Date:  2021-02-10       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.